|
Compound class:
Antibody
Comment: Livmoniplimab (ABBV-151, formerly ARGX-115 and MHG-8) is a chimeric, humanised IgG4-κ monoclonal antibody that targets LRRC32 (GARP)/transforming growth factor β1 (TGFβ1) complexes. It blocks LRRC32-mediated activation of latent TGFβ1, and was designed to block immunosuppressive Treg activity in tumours, as an immunooncology strategy.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Van Der Woning S, Borgions F, Dreier T, Mariën L, De Boeck G, Liénart S, Lucas S, Coulie P. (2019)
GARP-TGF-beta 1 antibodies. Patent number: US10479829B2. Assignee: argenx BVBA' Université Catholique de Louvian. Priority date: 11/05/2018. Publication date: 19/11/2019. |
